Form 4: IRADIMED CEO Sells Shares Under 10b5-1 Plan

IRADIMED Corp's CEO, President, and Chairman, Roger E. Susi, sold 5,000 shares of common stock on December 22, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• Roger E. Susi, who serves as CEO, President, and Chairman of IRADIMED Corp, executed the sale of a total of 5,000 shares of the company's common stock.
• The transactions took place on December 22, 2025.
• One sale involved 3,772 shares at a weighted average price of $96.42 per share, with individual trades ranging from $96.25 to $97.24.
• A second sale involved 1,228 shares at a weighted average price of $97.70 per share, with individual trades ranging from $97.36 to $98.24.
• These sales were conducted in accordance with a Rule 10b5-1 trading plan that Susi adopted on June 16, 2025.
• Following these reported transactions, Susi directly holds no shares, but maintains indirect beneficial ownership of 2,288,728 shares through the Phillip Susi 2008 Dynasty Trust, 162,950 shares through the Roger E. Susi Revocable Trust, and 2,062,500 shares through the Matthew Susi 2008 Dynasty Trust, though he disclaims beneficial ownership of the latter except for his pecuniary interest.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling by a key executive can be viewed negatively, the fact that the sales were conducted under a Rule 10b5-1 plan mitigates some of the concern, as it indicates a pre-planned financial move rather than a reaction to adverse company developments. The amount sold is significant but does not represent a complete divestment of the insider's holdings.

Positives

• The sales were executed pursuant to a pre-arranged Rule 10b5-1 trading plan, which indicates a planned disposition of shares rather than a reactive sale based on new, non-public information, potentially mitigating concerns about insider selling.

Negatives

• The sale of shares by a high-ranking insider, specifically the CEO, President, and Chairman, could be perceived negatively by the market, potentially signaling a lack of confidence or a belief that the stock price is at a high point.
• The total value of shares sold, approximately $484,000, represents a notable amount of capital being divested by a key executive.

Risks

• There is a potential for negative market perception due to insider selling, which could exert downward pressure on IRADIMED Corp's stock price, despite the sales being pre-planned.

Future Outlook

No forward-looking statements or guidance were provided in this filing.

Industry Context

This Form 4 filing details an individual insider transaction and does not provide information relevant to broader industry trends or competitive analysis.

Related Party Transactions

• Roger E. Susi maintains indirect beneficial ownership through family trusts, specifically the Phillip Susi 2008 Dynasty Trust and the Matthew Susi 2008 Dynasty Trust, as well as his own Roger E. Susi Revocable Trust. He disclaims beneficial ownership of the Matthew Susi 2008 Dynasty Trust shares except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders may interpret the insider sale as a negative signal, potentially leading to short-term downward pressure on the stock price. However, the context of a 10b5-1 plan may temper this reaction.
• No direct impact on employees, customers, suppliers, or creditors is indicated by this filing.

Key Dates

Recommendation

While the sale of shares by a high-level insider like the CEO could be a cause for concern, the execution under a Rule 10b5-1 plan suggests a pre-scheduled financial transaction rather than a reaction to new, negative company information. Given that the CEO retains substantial indirect ownership, a 'hold' recommendation is appropriate. Investors should continue to monitor the company's operational performance and future insider activity, rather than making a definitive investment decision based solely on this planned sale.

Keywords

IRADIMED, IRMD, Roger E. Susi, insider trading, Form 4, stock sale, 10b5-1 plan, beneficial ownership, CEO, Chairman, President